In the past few decades, gene therapy has mainly been focused on small interfering RNA silencing VEGFA gene to treat neovascular eye disease.[26] Since the rapid development of gene editing technology, there are now more studies using the CRISPR/Cas9 system to knock out the VEGFA gene to treat age‐related macular degeneration, diabetic maculopathy/retinopathy, and other retinal diseases in preclinical studies.[27] These studies have implied the feasibility and safety of the CRISPR/Cas9 system for depleting VEGFA expression. The gene discussed is VEGFA; the disease is diabetic maculopathy.